Study of Dasatinib, Androgen Deprivation Therapy and Radiation

Inclusion Criteria

• •PATIENT ELIGIBILITY
• •Conditions for Patient Eligibility
• •Histologically or pathologically confirmed adenocarcinoma of the prostate to be treated with radiation therapy and hormone therapy.
• •Intermediate, high or very high risk disease
• •* Intermediate-risk disease (clinical T2b or T2c stage or PSA 10 to 20 ng/mL or Gleason score 7)
• •* High-risk disease (Gleason score 8 to 10, serum PSA \> 20 ng/mL or T3a disease)
• •* Very high-risk disease (T3b or T4)
• •No prior pelvic or prostate radiation or chemotherapy for prostate cancer.
• •Bone scan within 12 weeks prior to registration. Equivocal bone scan findings are allowed if plain films are negative for metastasis.
• •ECOG performance status 0-1
• •Age \> 18
• •Required entry laboratory parameters within 14 days of study entry: Granulocytes ≥ 1500/µl; platelet count ≥ 100,000/µl; Hgb \> 8.0 g/dl; Creatinine \< 1.5 x the institutional ULN, mg/dl; Bilirubin ≤ 2x institutional upper limit of normal; AST ≤ 2.5 x upper limit of normal, Serum Na+, K+, Mg2+, Phosphate and Calcium within institutional normal range; PT and PTT \< 1.5 ULN
• •Life expectancy of at least 1 year
• •No concurrent anticancer therapy.
• •Peripheral neuropathy must be ≤ Grade 2
• •A male subject of fathering potential must use an adequate method of contraception throughout the study \[and for at least 4 weeks after the last dose of study drug\].
• •Ability to take oral medication (dasatinib must be swallowed whole)
• •Signed study-specific consent form prior to study entry
• •Conditions for Patient Ineligibility